阿根诺卡菌素 | 70695-02-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 中文名称: 阿根诺卡菌素
• 英文名称: (3R,4S,7S,8aS,10aR,11R,12R,13R,14R,14aS,14bS,E)-14-hydroxy-4-((R)-1-hydroxyethyl)-7-methoxy-1,3,13-trimethyl-6-oxo-3,4,6,7,8,8a,10a,11,12,13,14,14a-dodecahydro-11,14b-epoxynaphtho[2,1-e]oxecin-12-yl 1H-pyrrole-2-carboxylate
• 英文别名: nargenicin A1；nargenicin A；nargenicin；[(1S,3R,4R,5R,6R,7S,8R,11S,13S,16S,17R,18E)-6-hydroxy-16-[(1R)-1-hydroxyethyl]-13-methoxy-5,17,19-trimethyl-14-oxo-2,15-dioxatetracyclo[9.8.0.01,7.03,8]nonadeca-9,18-dien-4-yl] 1H-pyrrole-2-carboxylate
• CAS: 70695-02-2
• 化学式: C₂₈H₃₇NO₈
• 分子量: 515.604
• InChiKey: YEUSSARNQQYBKH-SIMZXIQRSA-N

物化性质

• 沸点：
  718.3±60.0 °C(Predicted)
• 密度：
  1.31±0.1 g/cm3(Predicted)
• 溶解度：
  DMF：可溶； DMSO：可溶；乙醇：可溶；甲醇：可溶

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  37
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  127
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  阿根诺卡菌素 在 2,6-二甲基吡啶 作用下， 以 二氯甲烷 、 1,2-二氯乙烷 为溶剂， 反应 43.5h， 生成 [(1S,3R,4R,5R,6R,7S,8R,13S,16S,17R,18E)-16-[(1R)-1-[tert-butyl(dimethyl)silyl]oxyethyl]-6-carbamoyloxy-13-methoxy-5,17,19-trimethyl-14-oxo-2,15-dioxatetracyclo[9.8.0.01,7.03,8]nonadeca-9,18-dien-4-yl] 1H-pyrrole-2-carboxylate
  参考文献：
  名称：

  [EN] NARGENICIN COMPOUNDS AND USES THEREOF AS ANTIBACTERIAL AGENTS
  [FR] COMPOSÉS NARGÉNICINE ET LEURS UTILISATIONS DE COMME AGENTS ANTIBACTÉRIENS

  摘要：

  本发明涉及一种新型的纳尔吉霉素相关化合物，可以抑制DnaE并具有抗细菌作用，特别是对结核分枝杆菌具有抗菌活性。本发明还涉及一种抑制分枝杆菌细胞生长的方法，以及通过给予纳尔吉霉素或纳尔吉霉素相关化合物及/或其药学上可接受的盐的抗结核菌有效量来治疗结核分枝杆菌感染的方法。

  公开号：

  WO2016061772A1

文献信息

• NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF BACTERIAL INFECTIOUS DISEASES
  申请人：GALAPAGOS NV

  公开号：US20160297830A1

  公开（公告）日：2016-10-13

  Compounds are disclosed that have a formula represented by the following: wherein A, B, R 1 , R 2 and R 3 are as defined herein. Novel compounds of the invention may be prepared as a pharmaceutical composition, and may be useful in the treatment of infectious diseases, in particular bacterial infectious diseases. The compounds may be active against a specific enzyme in the bacterial DNA replicative process, DNA polymerase IIIE.

  本发明揭示了具有以下表示的化合物：其中A、B、R1、R2和R3如本文所定义。本发明的新化合物可以制备为药物组合物，并且可能在治疗传染病方面有用，特别是细菌性传染病。这些化合物可能对细菌DNA复制过程中的特定酶DNA聚合酶IIIE具有活性。
• Nargenicin compounds and uses thereof as antibacterial agents
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10144741B2

  公开（公告）日：2018-12-04

  The present invention relates to novel nargenicin related compounds which can inhibit DnaE and have antibacterial, particularly antimycobacterial activity against Mycobacterium tuberculosis. The present invention also relates to method for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis by administering an antimycobacterially effective amount of nargenicin or a nargenicin-related compound and/or their pharmaceutically acceptable salts.

  本发明涉及可抑制 DnaE 并对结核分枝杆菌具有抗菌特别是抗霉菌活性的新型 nargenicin 相关化合物。本发明还涉及抑制分枝杆菌细胞生长的方法，以及通过施用抗分枝杆菌有效量的 nargenicin 或 nargenicin 相关化合物和/或它们的药学上可接受的盐类来治疗结核分枝杆菌感染的方法。
• NARGENICIN COMPOUNDS AND USES THEREOF AS ANTIBACTERIAL AGENTS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20170305924A1

  公开（公告）日：2017-10-26

  The present invention relates to novel nargenicin related compounds which can inhibit DnaE and have antibacterial, particularly antimycobacterial activity against Mycobacterium tuberculosis. The present invention also relates to method for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis by administering an antimycobacterially effective amount of nargenicin or a nargenicin-related compound and/or their pharmaceutically acceptable salts.
• US9944654B2
  申请人：——

  公开号：US9944654B2

  公开（公告）日：2018-04-17

表征谱图